Hybrid compounds as new Bcr/Abl inhibitors

Hybrid compounds as new Bcr/Abl inhibitors Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-AblT315I mutant Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents Design, synthesis and evaluation of (E)-α-benzylthio chalcones as novel inhibitors of BCR-ABL kinase Design, synthesis, and biological activity of 4-(imidazo[1,2- b ]pyridazin-3-yl)-1 H -pyrazol-1-yl-phenylbenzamide derivatives as BCR–ABL kinase inhibitors Synthesis and biological evaluation of novel aromatic amide derivatives as potential BCR-ABL inhibitors Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine Discovery of novel Bcr–Abl inhibitors targeting myristoyl pocket and ATP site Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR–ABL kinase